Sartorius Stedim Biotech presents new crossflow filtration system for process development
The ideal solution for scaling studies and low volume ultra- and diafiltration operations.
Sartorius Stedim Biotech (SSB) has launched SARTOFLOW Smart, the smart and easy benchtop crossflow system for optimized ultra- and diafiltration applications. It can ideally be used in many downstream processes, such as purification of vaccines, monoclonal antibodies and recombinant proteins. The system is suitable for flexible use in laboratory environments for process development and clinical trials as well as for cGMP environments.
The brand new system is equipped with a low shear 4-piston membrane pump that enables highest product yields to be achieved. In addition the pump provides a wide range of flow rates allowing to choose between membrane surface areas from 50 cm² to as much as 0.14 m².
The crossflow system is supplied with SSB’s intuitive and easy to use DCU-4 control unit, which, when combined with the company’s BioPAT SCADA, MFCS-4 software, provides data logging and export. Its touchscreen offers instant access to all critical process parameters and displays control and alarm functions. A logbook function stores alarms, set points and user logs.
The SARTOFLOW family of crossflow systems shares an unique operation design with a 7” touchscreen that supports the operator with interactive prompts for easy guidance through entire process sequences. Users can select predefined parameters to automatically run sequences for concentration, diafiltration, rinsing, filling, draining, flushing steps and tare functions.
An optional peristaltic diafiltration pump is available to load product or buffer as a discrete process step. Furthermore, several options are available to customize the system according to specific requirements. For example, a conductivity, pH or temperature probe can be installed in the recirculation vessel. The system can also be upgraded in the case of changing process requirements.
“SARTOFLOW Smart is a milestone development in the landscape of small crossflow systems. It combines outstanding technology with options that are normally only available with process systems. With an exceptionally wide working range of membrane surface areas, the system is the perfect tool for both R&D optimization trials and cGMP production,” stated Dr. Marc Jenke, expert for benchtop crossflow filtration systems at Sartorius Stedim Biotech.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...